SHS Gesellschaft für Beteiligungsmanagement mbH

The healthcare investor SHS Capital, together with its portfolio company Medizintechnik Rostock GmbH (MTR), has acquired Curatec Services GmbH (Curatec). Curatec is a specialist in medical electrical stimulation and rehabilitation devices based in North Rhine-Westphalia, Germany. The transaction expands MTR’s existing product portfolio, strengthens its market position in electrical stimulation with a particular focus on neurological applications, and secures Curatec’s succession.   Tübingen, 25 November 2025 SHS Capital, together with its portfolio company MTR, has acquired Curatec Services GmbH, an established provider of innovative electrical stimulation devices. The aim of the transaction is to secure Curatec’s proven expertise and product range for the long term, expand it within the MTR platform, and ensure that patients throughout Germany receive high-quality, innovative solutions in neurology and uro-gynaecology. Curatec Services GmbH is a specialised provider of medical electrical stimulation and rehabilitation devices for home use. The company focuses on therapies in neurology, uro-gynaecology, and orthopaedics. With more than 25 years of experience and a highly dedicated team, Curatec has established itself as an innovative niche provider known for high-quality medical devices and strong, patient-centred service. Thanks to established relationships with rehabilitation clinics, hospitals, specialist practices, and homecare providers, as well as trusted cooperations with statutory health insurers, Curatec enjoys an excellent reputation as a pioneer in electrotherapy. With this transaction, MTR and SHS continue their joint strategy to improve patient care through high-quality, technology-supported therapy solutions. Curatec expands the existing MTR portfolio with specialised solutions for neurological applications, functional electrical stimulation (FES), and incontinence therapy. Curatec’s strong regional presence in North Rhine-Westphalia also enhances MTR’s geographic footprint and opens new commercial opportunities in western Germany. The combined product portfolios and the integrated sales and service networks create significant synergies that will further improve patient access to modern therapy solutions. MTR and SHS intend to preserve Curatec’s proven technology platform and existing customer network while systematically expanding the offering in advanced electrotherapy. “We are pleased that SHS and MTR will continue and further develop our business. Preserving the trust in the quality of our work that we built over many years and ensuring that patients who urgently rely on our products continue to benefit from them, has been our priority,” says Curatec Managing Director Rainer Eckert. “By acquiring Curatec, we are strengthening our combined market presence and will have an even more comprehensive product portfolio in electrical stimulation therapy. This partnership provides an excellent foundation for further growth and the highest standards in patient care,” comments MTR Managing Director Andreas Markschies. “This acquisition exemplifies the SHS approach of guiding innovative medical technology companies into the next generation, creating sustainable succession solutions, and safeguarding patient care over the long term. Curatec is a company that ideally complements MTR in both product portfolio and regional footprint,” explains SHS Senior Investment Manager Tobias Fuchs.   About SHS Capital: SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. "Building European Healthcare Champions" is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 270 million. More information at: http://www.shs-capital.eu Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter
and follow us on LinkedIn   PR contact: Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
tuebingen@shs-capital.eu